Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]

Veerus, Piret; Hovi, Sirpa-Liisa; Fischer, Krista; Rahu, Mati; Hakama, Matti; Hemminki, Elina

doi:10.1016/j.maturitas.2006.01.012

Cited by 55 publications

(68 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was a trend toward an increase in cerebrovascular events in women taking the same dose and formulation of hormone therapy as in the WHI (HR, 1.24; 95% CI, 0.85 to 1.82). 381 The Kronos Early Estrogen Prevention Study (KEEPS) is an ongoing trial of women 42 to 58 years of age who are within 36 months of their final menstrual period and randomized to estrogen replacement in low doses (0.45 mg CEE), transdermal formulation (50 g/wk), and combined with cyclic oral, micronized progesterone 200 mg for 12 days each month. 382 The primary outcomes are progression of subclinical atherosclerosis as measured by carotid IMT and coronary calcium scores.…”

Section: Postmenopausal Hormone Therapymentioning

confidence: 99%

Guidelines for the Primary Prevention of Stroke

Goldstein¹,

Bushnell²,

Adams³

et al. 2011

Stroke

1,298

577

View full text Add to dashboard Cite

Background and Purpose-This guideline provides an overview of the evidence on established and emerging risk factors for stroke to provide evidence-based recommendations for the reduction of risk of a first stroke. Methods-Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association (AHA) Stroke Council Scientific Statement Oversight Committee and the AHA Manuscript Oversight Committee. The writing group used systematic literature reviews (covering the time since the last review was published in 2006 up to April 2009), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and when appropriate, formulate recommendations using standard AHA criteria (Tables 1 and 2). All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. The guideline underwent extensive peer review by the Stroke Council leadership and the AHA scientific statements oversight committees before consideration and approval by the AHA Science Advisory and Coordinating Committee. Results-Schemes for assessing a person's risk of a first stroke were evaluated. Risk factors or risk markers for a first stroke were classified according to potential for modification (nonmodifiable, modifiable, or potentially modifiable) and strength of evidence (well documented or less well documented). Nonmodifiable risk factors include age, sex, low birth weight, race/ethnicity, and genetic predisposition. Well-documented and modifiable risk factors include hypertension, exposure to cigarette smoke, diabetes, atrial fibrillation and certain other cardiac conditions, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, physical inactivity, and obesity and body fat

show abstract

Section: Postmenopausal Hormone Therapymentioning

confidence: 99%

Guidelines for the Primary Prevention of Stroke

Goldstein¹,

Bushnell²,

Adams³

et al. 2011

Stroke

1,298

577

View full text Add to dashboard Cite

show abstract

“…HRT is still delicate subject. Recently in Finland, the study of Veerus et al (2006) caused heavy debate in both public and professional media [16]. Long-term effect of this kind of debate could be that women with difficult menopausal symptoms do not dare to use HRT.…”

Section: Discussionmentioning

confidence: 99%

Do Finnish women using hormone replacement therapy need more information about risks

2007

View full text Add to dashboard Cite

show abstract

“…HRT appears to balance or slow-down this phenomenon and could therefore aid in maintaining proper muscle mass and function after menopause. However, in the light of the HRT-related risks reported in the Women's Health Initiative 64 and Estonian Postmenopausal Hormone Therapy trial 65 , the use of HRT should always be carefully considered and individual's family history and personal risk factors taken into account.…”

mentioning

confidence: 99%

Muscular Transcriptome in Postmenopausal Women With or Without Hormone Replacement

Pöllänen

Ronkainen

Suominen

et al. 2007

Rejuvenation Research

View full text Add to dashboard Cite

The loss of muscle mass and strength with aging is well characterized, but our knowledge of the molecular mechanisms underlying the development of sarcopenia remains incomplete. Although menopause is often accompanied with first signs of age-associated changes in muscle structure and function, the effects of hormone replacement therapy (HRT) or menopause-related decline in estrogen production in the muscles of postmenopausal women is not well understood.Furthermore the knowledge of the global transcriptional changes that take place in skeletal muscle in relation to estrogen status has thus far been completely lacking. We used a randomized double-blinded study design together with an explorative microarray experiment to characterize possible effects of continuous, combined HRT and estrogen deprivation on the skeletal muscle of fifteen women. Here, we report the differential response of both GO-annotated biological processes and some individual genes responding differentially to the use or non-use of HRT. Our results revealed transcription level changes in, e.g., muscle protein and energy metabolism. In particular, the ubiquitine-proteosome system was found to be effected at several levels. HRT seemed to partially counteract the postmenopause-related transcriptional changes. Our results suggest that during the early postmenopausal years, when there is no counteracting medication available, muscle transcriptome changes notably, whereas HRT appears to slow-down this phenomenon and could therefore aid in maintaining proper muscle mass and function after menopause.3

show abstract

Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]

Cited by 55 publications

References 35 publications

Guidelines for the Primary Prevention of Stroke

Guidelines for the Primary Prevention of Stroke

Do Finnish women using hormone replacement therapy need more information about risks

Muscular Transcriptome in Postmenopausal Women With or Without Hormone Replacement

Contact Info

Product

Resources

About